Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 3Solid Tumors 2Carcinoma, Hepatocellular 2Adult Solid Neoplasm 2Solid Neoplasm 1Sarcoma 1Neoplasm Metastasis 1Melanoma 1Fibrosis 1Childhood Solid Neoplasm 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 2sonidegib 1navitoclax 1Vitamin D 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide 1High-Energy Shock Waves 1Enkephalin, Methionine 1Biopsy 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Fibrosis × ARQ 197 × Clear all
NCT00802555 2012-07-12

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
21 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡